A recent Washington Post article discussed several new treatment and diagnostic options for Alzheimer’s that should bring some comfort to a disease in which up to now, there has been little hope. With an estimated number of Americans developing the disease expected to increase from approximately a half of million people in 2020 to a million by 2060, we all hope for answers.
Ronald Peterson, a professor of neurology and the former director of the Alzheimer’s Disease Research Center at the Mayo Clinic College of Medicine and Science, reports, “I think we are at the threshold of making a significant impact on the quality of life – the health span, not just the lifespan. “
One of those significant advances has been the FDA’s first ever approved blood test with over a 90 percent accuracy rate. The test detects the signals of amyloid beta plaques and tau tangles, which are the biological hallmarks of Alzheimer’s disease. The new test is much more accessible, more affordable and less invasive than the previous PET neuroimaging test. Experts say this will revolutionize diagnosing the disease and provide opportunity for earlier treatments and intervention.
Another encouraging step comes from the largest lifestyle intervention clinical trial known as U.S. POINTER. Its early reporting shows targeting multiple areas like nutrition, exercise, cognitive training, and health monitoring has helped to improve cognitive measures for those at risk for dementia.
Other findings producing hopeful results are the role vaccines may play in reducing dementia risk. One study tracked adults who received both the shingles and RSV vaccines with a lower risk for dementia. Experts say two things may be responsible. The first is that vaccines reduce the risk of infections and inflammation, which have been linked to an increase in dementia; or that the actual vaccines themselves may activate the immune system in a beneficial way.
Also, there has been talk about lithium carbonate, a drug that has treated bipolar disorder for quite some time, as having a role in treating Alzheimer’s. Researchers say there is compelling data pointing to the use of lithium orotate to reverse damage Alzheimer’s causes to the brain, but caution that much more research needs to be done.
MorningStar of Beaverton senior living community provides the area with trusted independent living, assisted living and memory care. We offer 66 independent and assisted living suites in a choice of floorplans and configurations (some as large as 974 square feet); and deliver style, comfort, services, amenities and location for a carefree lifestyle. For those suffering from Alzheimer’s and dementia-related diseases, we offer 38 memory care suites. Contact us to schedule a personalized tour to see our beautiful retirement communities firsthand.
No comments:
Post a Comment